Scouting report · HELP
#22Eric SoFounder
Co-founded Cybin/Helus Pharma; Executive Chair, interim CEO twice in 2025-26
- Born / age
- (50)
- Role
- Co-founder, Executive Chair & President
- In the role
- 6 yr
- Education
- Undergraduate degree McGill University
- Front Office rank
- #22 of 23
HELP
Stake value$60.7m5.8% · 4.4m shares · as of 1 Sep 2026
C−53 / 100
Scouting sheetas of 24 Sep 2026
Delivers guidance640 beat · 4 met · 0 missed · 1 withdrawn
Answers the question—no call reviewed yet
Capital allocation60company five-year record: neutral
Pay design10individual, strategic · company lost money
Skin in the game66stake worth $60.7m, 4× last year's pay
80%Hit rate
—Pay at risk
—Say-on-pay
—Airtime on calls
- Beat
- 0
- Met
- 4
- Missed
- 0
- Withdrawn
- 1
- Still open
- 2
- Answers on calls
- 0
- Questions dodged
- 0
- Dodges / 100 answers
- —
Personal and ownership data
Not on file yet: born, place of birth, citizenship, marital status.
What to weigh
Red flag 1
- FY2026 pay $13.57m, of which $12.63m was 1,907,439 shares earned when the company closed a $175m equity financing on 2025-10-31. His contract sets founder awards at 40% of the plan headroom freed by any financing of C$75m or more before 2026-12-31. It pays for raising capital, not for clinical or share-price resultssrc
Watch 5
- A further 1,046,899 RSUs were awarded to him on 2026-09-01, per his 13Dsrc
- Employment agreement terminable only on 48 months' notice plus accrued pay; his performance awards survive termination and vest immediately on itsrc
- 28.7% of votes withheld on his re-election as director at the 2026-09-22 meeting (Halstead, Glavine and Lewis-Hall drew a similar share); the four other independents got 95.8-99.7%src
- As Chair he oversaw three CEO changes in eleven months: Drysdale out 2025-09-02, Cola hired 2026-02-10 and removed at the board's request 2026-04-20 ($750k severance), Halstead in 2026-08-03src
- Five-year TSR to 2026-03-31 was about -82%, per the company's own performance graphsrc
In their favour 1
- Put about $3.57m of his own money into the stock in September 2026, days after the first Section 16 filings appeared for this namesrc
Pay
Salary and otherBonus, stock, options, incentive
The table
- Bonus pays on
- Discretionary cash bonus against performance objectives the Compensation Committee sets each year; no formula disclosed
- Long-term award pays on
- Contractual founder awards equal to 40% of the plan headroom created by financings of C$75m+ (2025-09-26 to 2026-12-31), vesting on termination; 2026 grant fully vestedsrc
- Pay at risk not on file
- Pays on returns individual, strategic
- Shareholder vote not on file
- Pay vs profit company lost money
Career
- 2026-08 – nowCybin Inc. (Helus Pharma)src
Executive Chair & President (co-founder)
Handed the CEO role to Michael Halstead on 2026-08-03; Form 3 title 'Executive Chair' (F3-SO-2026); Chair of the Board and not independent per CIRC-2026 - 2026-04 – 2026-08Cybin Inc. (Helus Pharma)src
Executive Chairman & Interim CEO (second spell)
Resumed interim CEO on 2026-04-20 when the board asked Michael Cola to step down after ten weeks - 2025-09 – 2026-02Cybin Inc.src
President & Interim CEO
Interim CEO 2025-09-02 to 2026-02-10 after Doug Drysdale stepped down - 2020-11 – 2025-09Cybin Inc.src
Co-founder, President and Director
Appointed November 2020 on the reverse takeover of Clarmin Explorations; described as co-founder and President of Cybin Corp. in July 2020 (CLARMIN-2020) - 2017-12 – 2018-12
- 2015 – 2020Trinity Venture Partners; Growpacker; Mundo Inc.src
Managing Director (Trinity Venture Partners); President (Growpacker); Special Advisor and General Counsel (Mundo Inc.)
Listed as his principal occupations over the five years before the 2020-07-15 circular; no individual dates given - 2006-04 – 2010-11
- 2000 – 2004Torys LLPsrc
Associate (corporate commercial, securities, finance, M&A)
The firm is named in CLARMIN-2020; the years come only from the search summary
Not located: 2004-2006 and 2010-2015 not located in any source searched; the 2015-2020 roles carry no individual dates; when Cybin Corp. was founded is not stated in any filing read (his Form 3 dates warrants he holds to 2019)
The promise ledger5 scored · 2 open
| Result | What was promised | Where it is scored | How |
|---|---|---|---|
| M Met | Repay indebtedness — $22,765 out of the October 2025 offering | HELP row 1 | written outlook |
| M Met | Initiate enrollment in EMBRACE — $1,196 | HELP row 2 | written outlook |
| M Met | Complete the Phase 2 GAD study — $1,292 | HELP row 3 | written outlook |
| M Met | Provide topline data from the Phase 2 GAD study — $810 | HELP row 4 | written outlook |
| W Withdrawn | ❗ HLP005 — deliver a drug development candidate by Q4 2026 | HELP row 5 | written outlook |
| · Still open | APPROACH topline efficacy readout in Q4 2026 (~$49,857 total, $23,686 remaining at 2026-03-31) | HELP row 6 | written outlook |
| · Still open | HLP004 — complete the design of the next study by the end of Q3 2026 (~$150, none spent at 2026-03-31) | HELP row 7 | written outlook |
Background
- Family His spouse holds 53,616 shares and is a co-filer on his Schedule 13D; the circular and AIF read contain no statement on family relationships among directors and officerssrc
- Founder Co-founder alongside Paul Glavine (founding CEO, now Chief Growth Officer); both have employment agreements terminable only on 48 months' noticesrc
- Boards Director of Riot Blockchain (Nasdaq) from October 2017 until he left the board in February 2018src
- Boards Director of Therapix Biosciences (Nasdaq) June 2017 to December 2019 and of Hyperblock (CSE) July 2018 to April 2019src
- Regulatory Was VP Corporate Strategy and General Counsel of Synergex when it was cease-traded on 2010-06-12 for failing to file its financial statements, MD&A and AIF; he left in November 2010src
- Personal Resident in Dubai, United Arab Emirates, per the 2026 circularsrc
Sources15
- Filing Cybin Inc. management information circular for the 2026 annual and special meeting, dated 2026-08-18 (Ex-99 to 6-K, acc 0001833141-26-000067) · 2026-08-18
- Filing Cybin Inc. Annual Information Form for the year ended 2026-03-31, dated 2026-06-29 (Ex-99.1 to 40-F, acc 0001833141-26-000046) · 2026-06-29
- Filing Cybin Inc. audited consolidated financial statements FY ended 2026-03-31 (Ex-99.2 to 40-F, acc 0001833141-26-000046) · 2026-06-29
- Filing Clarmin Explorations Inc. management information circular dated 2020-07-15 for the Cybin reverse takeover (Ex-99.8 to 40-F registration, acc 0001193125-21-224423) · 2020-07-15
- Filing Helus Pharma press release: CEO transition, Eric So to resume interim CEO (Ex-99.1 to 6-K, acc 0001833141-26-000024) · 2026-04-20
- Filing Helus Pharma press release: appoints Michael Halstead as CEO (Ex-99.1 to 6-K, acc 0001062993-26-003976) · 2026-08-03
- Filing Helus Pharma press release: results of 2026-09-22 annual and special meeting (Ex-99.1 to 6-K, acc 0001833141-26-000081) · 2026-09-22
- Filing Schedule 13D, Eric H. L. So and spouse, event date 2026-09-01 (acc 0000912282-26-001255) · 2026-09-09
- Filing Form 3, Eric H. L. So (reporting CIK 2116526), Executive Chair, event 2026-09-01 (acc 0000912282-26-001253) · 2026-09-09
- Filing Form 4, Eric H. L. So, open-market purchase 2026-09-01 (acc 0000912282-26-001254) · 2026-09-09
- Filing Form 4, Eric H. L. So, open-market purchase 2026-09-04 (acc 0000912282-26-001257) · 2026-09-10
- Filing Form 4, Eric H. L. So, open-market purchase 2026-09-08 (acc 0000912282-26-001261) · 2026-09-11
- Filing Riot Blockchain 8-K Item 5.02 (acc 0001079973-18-000125): Remo Mancini fills the vacancy left by Eric So · 2018-02-23
- Web search result WebSearch: Eric So Cybin education (summary: McGill undergraduate degree 1997, University of Windsor graduate degree 2000, Torys LLP associate 2000-2004) · 2026-09-24
- Call transcript Cybin fiscal Q2 2026 results call (2025-11-13), market data